You are here

uniQure

Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient

Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient

Benzinga

etranacogene dezaparvovec

clinical trials

Flag link:

Gene therapy for hemophilia: So close, yet so far away

Gene therapy for hemophilia: So close, yet so far away

BioPharma Dive

Flag link:

UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find

UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find

Fierce Biotech

clinical trials

etranacogene dezaparvovec

Flag link:

#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout

#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout

Endpoints

Flag link:

UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B

UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B

Seeking Alpha

etranacogene dezaparvovec

Flag link:

UniQure gets out the gate first in race for Huntington's gene therapy

UniQure gets out the gate first in race for Huntington's gene therapy

BioPharma Dive

clinical trials

Huntington's disease

Flag link:

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Biopharma Dive

valoctocogene roxaparvovec

Flag link:

UniQure presses go on Huntington’s gene therapy trial

UniQure presses go on Huntington’s gene therapy trial

Pharmaforum

Huntington's disease

clinical trials

Flag link:

Why Novo Nordisk should buy Uniqure

Why Novo Nordisk should buy Uniqure

EP Vantage

Flag link:

UniQure stays a step ahead in hemophilia B

UniQure stays a step ahead in hemophilia B

Biopharma Dive

clinical trials

Flag link:

Why biotech companies are often at the whim of things they cannot control, in one chart

Why biotech companies are often at the whim of things they cannot control, in one chart

Stat

Flag link:

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Yahoo/Benzinga

Sangamo Therapeutics

Catalyst Biosciences

Reata Pharmaceuticals

Vertex Pharmaceuticals

Gilead Sciences

TRACON Pharmaceuticals

Sorrento Therapeutics

Flag link:

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

Endpoints

Flag link:

UniQure snags patents on Huntington's gene therapy as it preps for the clinic

UniQure snags patents on Huntington's gene therapy as it preps for the clinic

Biopharma Dive

Huntington's disease

clinical trials

Flag link:

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

Investors Business Daily

Spark Therapeutics

Flag link:

Uniqure turns the screw on Spark and Pfizer

Uniqure turns the screw on Spark and Pfizer

EP Vantage

Spark Therapeutics

Flag link:

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

Fierce Biotech

Flag link:

Who will pay for CRISPR?

Who will pay for CRISPR?

Stat

Spark Therapeutics

Flag link:

Biotech firm pulls pioneering gene therapy due to no demand

Biotech firm pulls pioneering gene therapy due to no demand

Yahoo/Reuters

Flag link:

Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark

Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark

Fierce Biotech

Spark Therapeutics

Flag link:

Pages